Cancer incidence and mortality are rising worldwide; the authors note projections of increasing cases and deaths and emphasize the need for new molecularly targeted agents. The study focuses on NEK2, a serine/threonine kinase that is frequently amplified in diverse cancers and is implicated in chromosomal instability, aneuploidy, and activation of oncogenic pathways. Existing kinase inhibitors have not been fully optimized for clinical pharmacokinetic properties and cancer therapies remain limited by drug resistance, motivating in silico approaches to identify novel chemical matter prior to experimental testing.
The article is a bioRxiv preprint (not peer reviewed) posted August 06, 2026. The authors declared no competing interests.
The investigators constructed an energy‑optimized pharmacophore (E-pharmacophore) model to capture critical interaction features for NEK2 inhibition. This model was applied to screen the Enamine REAL library, a commercial collection described in the preprint as containing millions of compounds. The screening workflow used the E-pharmacophore to reduce the large library to candidate molecules matching the model’s interaction features prior to further evaluation.
Following the initial pharmacophore-based selection, the top hits were evaluated for pharmacodynamic and pharmacokinetic properties using ADMET profiling as part of the selection funnel. The preprint reports that ADMET filtering was applied to remove candidates with unfavorable predicted absorption, distribution, metabolism, excretion, or toxicity characteristics before subjecting compounds to docking protocols.
Filtered candidates were docked into the NEK2 structure using both standard precision (SP) and extra precision (XP) docking protocols. Docking produced quantitative scores for prioritized molecules. The authors report three lead compounds (designated compounds 1, 2, and 3) with top docking scores of -7.414, -8.037, and -7.562, respectively. These values reflect the relative predicted binding poses and ranking produced by the docking software used in the workflow.
To further estimate binding energetics, the study applied MM‑GBSA rescoring to the docked complexes. The estimated binding free energies reported for the three lead complexes were: -54.92 kcal/mol for compound 1, -54.18 kcal/mol for compound 2, and -49.23 kcal/mol for compound 3. These MM‑GBSA values were presented as supportive evidence of favorable predicted binding affinity for the selected hits.
The authors conducted molecular dynamics (MD) simulations of the NEK2–ligand complexes for 100 ns to evaluate dynamic stability under simulated conditions. The preprint states that the MD trajectories demonstrated stability of the complexes throughout the 100 ns simulations, which the authors interpret as further support for the viability of the identified ligands as NEK2 binders.
The combined in silico pipeline—E-pharmacophore screening, ADMET filtering, SP/XP docking, MM‑GBSA rescoring, and 100 ns molecular dynamics—produced three prioritized lead molecules with the reported docking scores and MM‑GBSA energies above. The preprint designates these as promising NEK2 inhibitor candidates based on predicted binding and dynamic behavior.
The authors conclude that the three identified compounds merit experimental follow-up. Specifically, they recommend in vitro and in vivo validation to confirm NEK2 inhibition, determine cellular activity, assess pharmacokinetics, and evaluate safety. As this work is presented as a preprint, it has not undergone peer review; the manuscript does not provide experimental (biochemical or cellular) validation data within the reported study and therefore the reported candidate status is based solely on in silico evidence described above.
Clinicians and researchers should view these findings as hypothesis‑generating: the presented computational results prioritize compounds for experimental testing but do not establish efficacy, selectivity, or safety. Further laboratory and translational studies are required to determine whether these candidates can progress toward clinical development as NEK2 kinase inhibitors.